Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.
Journal
The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
26
02
2020
revised:
28
04
2020
accepted:
30
04
2020
pubmed:
21
6
2020
medline:
23
6
2021
entrez:
21
6
2020
Statut:
ppublish
Résumé
Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures. To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries. We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes. A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins. The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.
Sections du résumé
BACKGROUND
Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures.
OBJECTIVES
To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries.
METHODS
We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes.
RESULTS
A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins.
CONCLUSIONS
The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.
Identifiants
pubmed: 32562543
pii: 5860393
doi: 10.1093/jac/dkaa221
pmc: PMC7443737
doi:
Substances chimiques
Anti-Bacterial Agents
0
Vancomycin
6Q205EH1VU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2424-2431Subventions
Organisme : NIAID NIH HHS
ID : K24 AI121296
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI134637
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI143229
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Microb Drug Resist. 2015 Feb;21(1):25-34
pubmed: 25535825
J Clin Microbiol. 2011 Jan;49(1):177-83
pubmed: 21048008
Infect Genet Evol. 2014 Jan;21:575-82
pubmed: 23567819
Antimicrob Agents Chemother. 2009 Nov;53(11):4580-7
pubmed: 19506057
Antimicrob Agents Chemother. 2002 Jul;46(7):2155-61
pubmed: 12069968
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
J Antimicrob Chemother. 2007 Jul;60(1):42-8
pubmed: 17468509
Emerg Infect Dis. 2015 Oct;21(10):1844-8
pubmed: 26402569
Antimicrob Agents Chemother. 2013 Jan;57(1):83-95
pubmed: 23070169
N Engl J Med. 2014 Apr 17;370(16):1524-31
pubmed: 24738669
Braz J Infect Dis. 2015 Sep-Oct;19(5):466-72
pubmed: 26303003
J Clin Microbiol. 2012 Apr;50(4):1355-61
pubmed: 22238442
Antimicrob Agents Chemother. 2006 Feb;50(2):428-38
pubmed: 16436693
Science. 2020 Jan 10;367(6474):200-204
pubmed: 31919223
J Antimicrob Chemother. 1997 Jul;40(1):135-6
pubmed: 9249217
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28760895
Nucleic Acids Res. 2016 Jul 8;44(W1):W242-5
pubmed: 27095192
J Antimicrob Chemother. 2009 Mar;63(3):489-92
pubmed: 19136530
J Clin Microbiol. 2010 Feb;48(2):568-74
pubmed: 19940054
Nucleic Acids Res. 2014 Jan;42(Database issue):D206-14
pubmed: 24293654
Clin Microbiol Rev. 2010 Jan;23(1):99-139
pubmed: 20065327
PLoS One. 2012;7(1):e29573
pubmed: 22253738
Sci Rep. 2018 May 18;8(1):7868
pubmed: 29777150
Antimicrob Agents Chemother. 2013 Dec;57(12):5843-53
pubmed: 24018261
Front Microbiol. 2017 Jan 10;7:2163
pubmed: 28119680
Bioinformatics. 2015 Nov 15;31(22):3691-3
pubmed: 26198102
Biosci Biotechnol Biochem. 2018 May;82(5):741-751
pubmed: 29514560
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Clin Infect Dis. 2009 Dec 15;49(12):1861-7
pubmed: 19911971
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
PLoS One. 2016 Aug 30;11(8):e0160506
pubmed: 27575698
Yale J Biol Med. 2017 Jun 23;90(2):269-281
pubmed: 28656013
J Clin Microbiol. 2015 Nov;53(11):3543-6
pubmed: 26311860
Adv Exp Med Biol. 2008;631:214-28
pubmed: 18792692
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
Clin Infect Dis. 2014 Jan;58 Suppl 1:S10-9
pubmed: 24343827
Antimicrob Agents Chemother. 2010 Feb;54(2):945-9
pubmed: 19949062
Antimicrob Agents Chemother. 2011 Sep;55(9):4188-95
pubmed: 21746940
Eur J Clin Microbiol Infect Dis. 2012 May;31(5):739-45
pubmed: 21822974
J Infect Chemother. 2014 Sep;20(9):527-34
pubmed: 25066429
Int J Med Microbiol. 2005 Mar;294(8):479-86
pubmed: 15790292
Diagn Microbiol Infect Dis. 2014 Aug;79(4):401-4
pubmed: 24906792
Clin Infect Dis. 2008 Mar 1;46(5):668-74
pubmed: 18257700
Rev Chilena Infectol. 2015 Oct;32(5):588-90
pubmed: 26633120
J Vis Exp. 2013 Sep 05;(79):
pubmed: 24056633
J Antimicrob Chemother. 2001 Apr;47(4):399-403
pubmed: 11266410
Eur J Clin Microbiol Infect Dis. 2017 Aug;36(8):1473-1481
pubmed: 28337607
Lancet. 1997 Dec 6;350(9092):1670-3
pubmed: 9400512
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28232309
J Clin Microbiol. 1995 Sep;33(9):2233-9
pubmed: 7494007
PLoS One. 2015 Aug 19;10(8):e0136082
pubmed: 26287490
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500
Antimicrob Agents Chemother. 2016 May 23;60(6):3730-42
pubmed: 27067329
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147